Jam

Ascendis Pharma unveiled an ambitious 2026 roadmap, projecting significant revenue growth driven by YORVIPATH and SKYTROFA. The company anticipates around €720 million in revenue for 2025 and aims for €500 million in operating cash flow by 2026. Key pipeline advancements include potential approval for TransCon CNP and promising combination therapies. Strategic collaborations and a $120 million share repurchase program underscore Ascendis’ transition to a global biopharma leader.

Main Street Financial Services Corp. is increasing its quarterly cash dividend by 7% to $0.15 per share, reflecting confidence in its financial stability and operational performance. The $1.5 billion holding company, with 20 branches across Ohio and West Virginia, attributes this hike to its strong banking franchise and customer trust. This move signals a positive outlook for investors seeking income, though the increase is a measured step.

Toll Brothers is launching new ranch home designs at Aurora Ridge at Great Sky in Georgia, catering to demand for single-level living with open-concept layouts and upscale features. Priced from the low $500,000s, these homes offer a resort-style community experience. This move aligns with broader strength observed across the homebuilding sector, with several other major builders also showing positive stock performance, suggesting a favorable market environment for residential construction.

Sun Life U.S. has earned a spot on the 2025 Top Places to Work list by The Baltimore Sun, adding to previous recognitions across multiple U.S. locations. This award highlights the company’s commitment to employee well-being and growth through its supportive culture, comprehensive benefits, and flexible work model. Sun Life U.S. focuses on valuing employee contributions and fostering a purpose-driven environment, as evidenced by its high engagement and retention rates.

ECD Automotive Design and Chelsea Truck Company unveil the ECDxCTC Defender 02, a new Defender 110 P525 V8 in Carpathian Grey. It features Chelsea Truck Company’s Series 2 Wide Track body kit, 22-inch wheels, carbon fiber elements, and a powerful 5.0L supercharged V8 engine. The interior boasts Volcanic Black leather. This collaboration emphasizes unique styling and performance for automotive enthusiasts.

Rigel Pharmaceuticals has granted stock options and restricted stock units to 11 non-executive employees under its Inducement Plan. This initiative, approved by the Compensation Committee, aims to attract and retain talent by aligning employee incentives with company growth. Awards vest over four years, with a one-year cliff. This equity-based compensation strategy is common in the biotech sector to foster employee commitment and shareholder value.

Kezar Life Sciences secured an FDA meeting to discuss zetomipzomib for autoimmune hepatitis. The meeting will focus on designing a Phase 2b clinical study for relapsed and refractory AIH patients. Kezar provided pharmacokinetic and safety data, seeking to amend monitoring requirements and align on trial conduct. This move aims to advance zetomipzomib, a potential treatment for a serious condition with unmet needs.

European businesses are increasingly adopting sovereign cloud solutions for enhanced data autonomy, driven by stricter regulations, geopolitical concerns, and the rise of AI. This shift moves sovereign cloud from a compliance tool to a core IT strategy, prioritizing resilience, transparency, and local governance. Cloud providers are responding with advanced security measures and EU-specific offerings, with both global hyperscalers and regional players investing in localized infrastructure and governance models.

ASE Technology Holding reported strong 2025 results, with consolidated net revenues reaching approximately US$20.8 billion, an 11.8% increase year-over-year. The fourth quarter also saw robust growth. Demand for advanced packaging and testing services, driven by AI, 5G, and complex ICs, fueled this performance. The Advanced Technology Materials segment showed significant year-over-year revenue growth, highlighting its critical role in next-generation chip manufacturing.

Monte Rosa Therapeutics is raising approximately $300 million through a public offering of common stock and pre-funded warrants. This financing aims to fuel the advancement of their novel molecular glue degrader (MGD) medicines, particularly in autoimmune diseases, oncology, and other areas. The capital infusion follows positive clinical data presentations, bolstering investor confidence and supporting the company’s proprietary QuEEN™ discovery engine.